loader from loading.io

June 2022 Neurology Recall: Aducanumab's Approval, One Year Later

Neurology® Podcast

Release Date: 06/01/2022

July 2022 Neurology Recall: Topics in Epilepsy show art July 2022 Neurology Recall: Topics in Epilepsy

Neurology® Podcast

The July 2022 replay of past episodes showcases a selection of interviews that provide a wealth of insight into a variety of topics in epilepsy. This episode features Dr. Halley Alexander in conversation with Drs. Emanuela Voinescu, Ezequiel Gleichgerrcht, Nishant Sinha, and Alison Pack on seizure frequency during pregnancy and postpartum, the anatomy of surgical lesions and outcomes in temporal lobe epilepsy, predicting seizure recurrence via brain networks, and the AAN Guideline Subcommittee's practice advisory for antiseizure medication withdrawal, respectively.

info_outline
Antisense Oligonucleotide Suppression of C9orf72 show art Antisense Oligonucleotide Suppression of C9orf72

Neurology® Podcast

Dr. Jeff Ratliff discusses the suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide with Drs. Jonathan Watts and Robert Brown.

info_outline
COVID Brain Fog and Other Cognitive Syndromes show art COVID Brain Fog and Other Cognitive Syndromes

Neurology® Podcast

Dr. Gregg Day talks with Dr. Avi Nath, Clinical Director of the National Institute of Neurological Disorders and Stroke (NINDS), about COVID brain fog and other cognitive syndromes. Read the .

info_outline
Corticosteroids in LGI1 Antibody Encephalitis show art Corticosteroids in LGI1 Antibody Encephalitis

Neurology® Podcast

Dr. Justin Abbatemarco talks with Prof. Sarosh Irani about the use of corticosteroids as a first-line agent in the treatment of LGI1 antibody encephalitis.

info_outline
NINDS Mission and Clinical Neurology with Walter Koroshetz show art NINDS Mission and Clinical Neurology with Walter Koroshetz

Neurology® Podcast

Dr. Gregg Day talks with Dr. Walter Koroshetz, Director of the National Institute of Neurological Disorders and Stroke, about NINDS's mission and clinical neurology.

info_outline
Medicare Limitation of Aduhelm show art Medicare Limitation of Aduhelm

Neurology® Podcast

Dr. Jeff Burns talks with Dr. Ron Petersen, Director of the Mayo Clinic Alzheimer's Disease Research Center, about Medicare's recent decision to officially limit Aduhelm (aducanumab) coverage to patients in clinical trials. Read the .

info_outline
EEG Patterns and Neurofilament Light After Cardiac Arrest show art EEG Patterns and Neurofilament Light After Cardiac Arrest

Neurology® Podcast

Dr. Karen Hirsch talks with Dr. Linnéa Grindegård about the association between EEG patterns and serum neurofilament light as a marker of neuroaxonal injury after cardiac arrest. Read the . 

info_outline
Race-Ethnic Disparities in Stroke Thrombolysis show art Race-Ethnic Disparities in Stroke Thrombolysis

Neurology® Podcast

Drs. B.J. Hicks and Andy Southerland talk with Dr. Scott Mendelson about racial and ethnic disparities in the rates of declination of thrombolysis in patients with acute ischemic stroke. Read the .

info_outline
A Review of L-arginine in MELAS show art A Review of L-arginine in MELAS

Neurology® Podcast

Dr. Justin Abbatemarco talks with Prof. Gráinne Gorman about the use of L-arginine in the treatment of mitochondrial encephalopathy, lactic acidosis, and strokelike episodes (MELAS). Read the . 

info_outline
Pure Sleep Epilepsy in Patients With First Seizure show art Pure Sleep Epilepsy in Patients With First Seizure

Neurology® Podcast

Dr. Fábio Nascimento talks with Dr. Elaine Pang about the identification and characterization of pure sleep epilepsy after first-ever seizures from sleep in adults. Read the . 

info_outline
 
More Episodes

The June 2022 replay of past episodes showcases a selection of interviews about the impact of the FDA's approval of aducanumab for the treatment of Alzheimer disease (AD). This episode features illuminating conversations with Drs. Gregg Day, Ron Petersen, and Jason Karlawish on the clinical science guiding amyloid-based treatments for AD, the importance of patient participation when considering the use of aducanumab, and the business of Alzheimer disease, respectively. This month's Recall concludes with an interview featuring Pulitzer Prize-winning journalist Pam Belluck on Medicare's limitations on aducanumab coverage.